Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse (FABOLUS PRO)

This study has been completed.

Sponsor:

Information provided by:

Università degli Studi di Ferrara

ClinicalTrials.gov Identifier:

NCT01336348

First received: April 13, 2011

Last updated: October 9, 2012

Last verified: October 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2012
Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

No publications provided by Università degli Studi di Ferrara

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012 Mar;5(3):268-77.

To Top